Supported By : Ministry of Health & Family Welfare
Approved By : Ministry of Commerce
Online Media Partner :
Organized By :
The 8th International Exhibition on Asian Pharmaceutical Industries
February 24 – 26, 2011 Venue: Bangabandhu International Conference Centre, Dhaka, Bangladesh
Pharmaceutical Sector of Bangladesh
In Bangladesh, the pharmaceutical sector is one of the fastest growing sectors.. In 2008 the total size of the pharma
market in Bangladesh was estimated to be USD 700 million and is growing at a steady rate. The pharmaceutical sector is
the second highest contributor to the National Ex-Checker and the largest white collar labour intensive employment
sector of the country. There are 245 registered pharmaceutical manufacturing companies in Bangladesh. The local
pharmaceutical manufacturers cater to about 97% of the internal demand.
Today, Bangladesh Pharmaceutical Industry is successfully exporting APIs and a wide range of products covering all major
therapeutic classes and dosage forms to 71 countries. Beside regular forms like; Tablets, Capsules & Syrups, Bangladesh
is also exporting high-tech specialized products like HFA Inhalers, CFC Inhalers, Suppositories, Nasal Sprays, Injectables, IV Infusions, etc. are also being
exported from Bangladesh, and have been well accepted by the Medical Practitioners, Chemists, Patients and the Regulatory Bodies of all the importing
nations. The packaging and the presentation of the products of Bangladesh are comparable to any international standard and have been accepted bythem.
The Pharma Industry of Bangladesh is now on the verge of entering highly regulated overseas markets like USA and Europe. In this connection, several pharmaceutical manufacturers have already made huge investments in their new state of art manufacturing facilities. A number of companies have already obtained or in the process of obtaining UKMHRA, EU, TGA, AUSTRALIA and GCC certifications.
The future of pharmaceutical exports from Bangladesh is bright. After the inclusion of the Doha declaration in WTO / TRIPS Agreement, each and every
country belonging to the LDC Category has the option not to opt for pharmaceutical product patent until 2016, which means they can now legally reverseengineer
patented products and sell in their markets as well as can export to other LDCs. This creates a huge export opportunities for Bangladesh,
because, among all the 50 LDCs, Bangladesh is the only country which had a strong base for the pharma manufacturing. Besides direct export operations,
there is also a huge opportunity for the Bangladeshi companies to go for the Contract Manufacturing and compulsory licensing. The good news is, the
leading pharmaceutical exporters of Bangladesh have already started availing these opportunities.
